These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31553467)

  • 21. The States as Important Laboratories for Federal Prescription Drug Cost-Containment Efforts.
    Horvath JC; Anderson GF
    JAMA; 2019 Apr; 321(16):1561-1562. PubMed ID: 31012941
    [No Abstract]   [Full Text] [Related]  

  • 22. 'Must-pass' FDA fee renewal jammed with sunscreen and more.
    Scheinbaum C
    Nat Med; 2012 Jul; 18(7):990. PubMed ID: 22772529
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug Imports: The New Idea That's Kind of Old.
    Kirkner RM
    Manag Care; 2016 May; 25(5):12-3. PubMed ID: 27351059
    [No Abstract]   [Full Text] [Related]  

  • 24. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 26. Shades of gray. Secondary drug distributors raise questions.
    Lee J
    Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
    Neumann PJ; Cohen JT; Ollendorf DA
    N Engl J Med; 2021 Nov; 385(21):1923-1924. PubMed ID: 34767318
    [No Abstract]   [Full Text] [Related]  

  • 28. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 30. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 33. Running short.
    Mettner J
    Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 35. Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
    Conti RM; David FS
    F1000Res; 2020; 9():707. PubMed ID: 33204410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 37. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
    May D
    Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 39. The Future of Drug-Pricing Transparency.
    Feldman WB; Rome BN; Avorn J; Kesselheim AS
    N Engl J Med; 2021 Feb; 384(6):489-491. PubMed ID: 33440087
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-38. PubMed ID: 28252886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.